Nonclinical precedent Request an invite

Lynozyfic: animal efficacy model or human cells?

linvoseltamab · BCMA x CD3
Efficacy evidence
NSG mice co-implanted with human PBMC and NCI-H929 or MOLP-8 myeloma xenografts
“In vivo studies were performed to evaluate the anti-tumor efficacy and minimum effective dose of linvoseltamab in immunodeficient NSG mice SC co-implanted with human PBMC and either NCI-H929 (BCMA-high) or MOLP-8 (BCMA-low) MM cells.”
✓ VerifiedFDA multi-discipline review, p. 74Source ↗
Why that model
Binds human and cynomolgus monkey BCMA but not rat or mouse BCMA
“Overall, data indicate that linvoseltamab bound human and Cynomolgus monkey BCMA, but not rat or mouse BCMA.”
✓ VerifiedEMA assessment report, p. 27Source ↗
Reviewer's view of the efficacy data
EMA: efficacy demonstrated in the xenograft models
“Overall, linvoseltamab efficacy was demonstrated in the above-described xenograft models.”
✓ VerifiedEMA assessment report, p. 36Source ↗

Same question, other bispecifics

Bizengri

zenocutuzumab · HER2 x HER3
Mouse xenografts: HER2+ breast cancer (JIMT-1) and NRG1 fusion-positive lung and pancreatic patient-derived xenografts

Blincyto

blinatumomab · CD19 x CD3
Blinatumomab in NOD/SCID mouse tumor xenograft models

Columvi

glofitamab · CD20 x CD3
Human HSC-engrafted NOG/NSG mice, non-tumor-bearing and tumor-bearing

Elrexfio

elranatamab · BCMA x CD3
Multiple myeloma xenograft models (MM.1S, OPM2, MOLP8) with varying BCMA expression

Epkinly

epcoritamab · CD20 x CD3
Human lymphoma cell line-derived xenograft (CDX) mouse models and one patient-derived xenograft (PDX) model

Hemlibra

emicizumab · FIXa x FX
Cynomolgus monkey models of acute and chronic hemophilia A

Imdelltra

tarlatamab · DLL3 x CD3
Xenograft models in NSG mice injected with activated, expanded human T cells

Kimmtrak

tebentafusp · CD3 x gp100 (TCR fusion)
Mice engrafted with HLA-A*02:01/gp100+ Mel526 human melanoma cells plus human PBMCs; tumor growth inhibition

Korjuny

catumaxomab · EpCAM x CD3
SCID mouse i.p. human ovarian carcinoma ascites xenograft treated with human PBMCs plus catumaxomab

Lunsumio

mosunetuzumab · CD20 x CD3
Human CD20/CD3 double-transgenic mice: peripheral and tissue B-cell depletion and T-cell activation (comparable to analogue 2H7v16/40G5c)

Ordspono

odronextamab · CD20 x CD3
Lymphoma tumour models in humanized (BRG) mice and immunodeficient NSG mice

Removab

catumaxomab · EpCAM x CD3
Human ovarian carcinoma xenograft (catumaxomab); syngeneic human-EpCAM mouse tumour model with surrogate BiLu

Rybrevant

amivantamab · EGFR x MET
Patient-derived tumor xenografts with EGFR exon 20 insertion mutations in mice

Talvey

talquetamab · GPRC5D x CD3
Myeloma cell line xenografts (H929 prophylactic; MM.1S, RPMI 8226 established) in humanized immunodeficient mice

Tecvayli

teclistamab · BCMA x CD3
Human MM xenografts (H929, RPMI-8226) in human PBMC/T-cell-engrafted NSG mice

Vabysmo

faricimab · VEGF-A x Ang-2
Laser-induced choroidal neovascularization (nAMD model) in cynomolgus monkeys, IVT faricimab vs ranibizumab

Ziihera

zanidatamab · HER2 x HER2 (biparatopic)
HER2 3+ xenografts in nude mice (SKOV-3, NCI-N87, patient-derived GXA 3054); no effect in HER2-negative model

Summary across all 18 bispecifics →